Researchers say that a drug used to treat enlarged prostates may also slow the growth of tumors in men with low-risk prostate cancer who opt to be monitored instead of getting treated right away.
A study found that men taking the drug Avodart were less likely to see their cancer worsen over the next three years than men taking dummy pills.
Doctors say the results may persuade more men to choose medical monitoring, or “watchful waiting,” instead of immediate treatment. Many people are being treated now for cancers that are not life-threatening, and suffering urinary or sexual side effects.
The study of GlaxoSmithKline PLC’s drug will be presented later this week at a cancer conference in Florida.
